We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Merck & Co, Shopify, Intercontinental Exchange, Barrick Gold Corp and NXP Semiconductors
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 22, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck & Co., Inc. (MRK - Free Report) , Shopify Inc. (SHOP - Free Report) , Intercontinental Exchange, Inc. (ICE - Free Report) , Barrick Gold Corp. (GOLD - Free Report) and NXP Semiconductors N.V. (NXPI - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Merck, Shopify and Intercontinental Exchange
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc., Shopify Inc. and Intercontinental Exchange, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Merck have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+2.8% vs. +16.9%), although the company beat Q4 estimates for earnings and sales. The Zacks analyst believes that drugs like Keytruda, Lynparza and Bridion have been driving sales.
Keytruda sales are gaining from continued lung cancer diagnoses, and increasing usage in other cancer indications. Animal health and vaccine products remain core growth drivers. Its new oral antiviral pill for COVID-19, molnupiravir, will be a key top-line driver in 2022.
Merck boasts a strong cancer pipeline, including Keytruda, which should help drive long-term growth. However, generic competition for several drugs and rising competitive pressure, mainly on the diabetes franchise, will continue to be overhangs on the top line.
Shares of Shopify have underperformed the Zacks Internet - Services industry over the past two-year period (+21.5% vs. +42.0%), though the company is benefiting from e-commerce boom-induced growth in the merchant base. Robust uptick in Shopify Shipping, Shopify Pay and Shopify Capital is driving the top line as reflected by fourth quarter results. The company has been focused on winning merchants on a regular basis, based on product offerings including Shop Pay and Shop Pay Installments, as well as features like end-to-end order tracking.
The Zacks analyst believes that solid adoption of new merchant-friendly applications holds promise, while partnerships with Facebook, Instagram and Google are expected to expand its merchant base. However, higher investments on product development as well as fulfillment platforms are likely to limit margin expansion in the near term. Raging inflation and cautious consumer spending is expected to hurt top-line growth in the near term.
Shares of Intercontinental Exchange have outperformed the Zacks Securities and Exchanges industry over the past six month period (+5.9% vs. +0.2%). The Zacks analyst believes that Intercontinental Exchange’s top line benefits from its compelling product and service portfolio, broad range of risk management services, strength in global data services. Continued strength in its energy franchise, improving recurring market data revenues are likely to keep growth on track.
Strategic buyouts help it achieve cost synergies that are in sync with its aim of generating long-term value for shareholders. It is well-poised for growth on the back of accelerated digitization taking place in the US residential mortgage industry. A solid balance sheet helps in effective capital deployment. Shares have outperformed the industry in the past six months. However, its expenses are likely to remain high in the near term.
Other noteworthy reports we are featuring today include Barrick Gold Corp. and NXP Semiconductors N.V.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free.Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Merck & Co, Shopify, Intercontinental Exchange, Barrick Gold Corp and NXP Semiconductors
For Immediate Release
Chicago, IL – February 22, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck & Co., Inc. (MRK - Free Report) , Shopify Inc. (SHOP - Free Report) , Intercontinental Exchange, Inc. (ICE - Free Report) , Barrick Gold Corp. (GOLD - Free Report) and NXP Semiconductors N.V. (NXPI - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Merck, Shopify and Intercontinental Exchange
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc., Shopify Inc. and Intercontinental Exchange, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Merck have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+2.8% vs. +16.9%), although the company beat Q4 estimates for earnings and sales. The Zacks analyst believes that drugs like Keytruda, Lynparza and Bridion have been driving sales.
Keytruda sales are gaining from continued lung cancer diagnoses, and increasing usage in other cancer indications. Animal health and vaccine products remain core growth drivers. Its new oral antiviral pill for COVID-19, molnupiravir, will be a key top-line driver in 2022.
Merck boasts a strong cancer pipeline, including Keytruda, which should help drive long-term growth. However, generic competition for several drugs and rising competitive pressure, mainly on the diabetes franchise, will continue to be overhangs on the top line.
(You can read the full research report on Merck here >>>)
Shares of Shopify have underperformed the Zacks Internet - Services industry over the past two-year period (+21.5% vs. +42.0%), though the company is benefiting from e-commerce boom-induced growth in the merchant base. Robust uptick in Shopify Shipping, Shopify Pay and Shopify Capital is driving the top line as reflected by fourth quarter results. The company has been focused on winning merchants on a regular basis, based on product offerings including Shop Pay and Shop Pay Installments, as well as features like end-to-end order tracking.
The Zacks analyst believes that solid adoption of new merchant-friendly applications holds promise, while partnerships with Facebook, Instagram and Google are expected to expand its merchant base. However, higher investments on product development as well as fulfillment platforms are likely to limit margin expansion in the near term. Raging inflation and cautious consumer spending is expected to hurt top-line growth in the near term.
(You can read the full research report on Shopify here >>>)
Shares of Intercontinental Exchange have outperformed the Zacks Securities and Exchanges industry over the past six month period (+5.9% vs. +0.2%). The Zacks analyst believes that Intercontinental Exchange’s top line benefits from its compelling product and service portfolio, broad range of risk management services, strength in global data services. Continued strength in its energy franchise, improving recurring market data revenues are likely to keep growth on track.
Strategic buyouts help it achieve cost synergies that are in sync with its aim of generating long-term value for shareholders. It is well-poised for growth on the back of accelerated digitization taking place in the US residential mortgage industry. A solid balance sheet helps in effective capital deployment. Shares have outperformed the industry in the past six months. However, its expenses are likely to remain high in the near term.
(You can read the full research report on Intercontinental Exchange here >>>)
Other noteworthy reports we are featuring today include Barrick Gold Corp. and NXP Semiconductors N.V.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free.Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.